Serotonin dimers: Application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists

Journal of Medicinal Chemistry

Volumn 39, Issue 25, 1996, Pages 4920-4927

  Halazy, Serge ^a   Perez, Michel ^a   Fourrier, Catherine ^a   Pallard, Isabelle ^a   Pauwels, Petrus J ^a   Palmier, Christiane ^a   John, Gareth W ^a   Valentin, Jean Pierre ^a   Bonnafous, Régine ^a   Martinez, Jean ^b  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; DIMER; DRUG CARRIER; FORSKOLIN; PIPERAZINE DERIVATIVE; RECEPTOR SUBTYPE; SEROTONIN 1 AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN DERIVATIVE; SUMATRIPTAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; LIGAND BINDING; NONHUMAN; RABBIT; SAPHENOUS VEIN; SEROTONINERGIC SYSTEM; VENOCONSTRICTION;

ANIMALS; BIOPOLYMERS; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; RABBITS; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN AGONISTS;

EID: 10544224535     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960552l     Document Type: Article

References (41)

1. Glennon, R. A. Serotonin receptors: clinical implications. Neurosci. Biobehav. Rev. 1990, 14, 35-47.
2. (a) Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. A. Pharmacol. Rev. 1994, 46, 157-203.
3. (b) Peroutka, S. J. Serotonin receptor subtypes. CNS Drugs 1995, 4 (Suppl. 1),18-28.
4. 1D receptor subtypes. TIPS 1996, 17, 103-105.
5. (a) Saudou, F.; Hen, R. 5-HT receptor subtypes: Molecular and functional diversity. Med. Chem. Res. 1994, 4, 16-84.
6. 1D receptors. Biol. Signals 1994, 3, 217-222.
7. 1B receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1906, 353, 144-156.
8. 1Dβ" receptors. Eur. J. Pharmacol. 1993, 242, 75-82.
9. (b) Kaumann, A. J.; Parsons, A. A.; Brown, A. M. Human arterial constrictor serotonin receptors. Cardiovasc. Res. 1993, 27, 2094-2103.
10. 1Dα serotonin receptor gene expression in trigeminal ganglia: Implications for antimigraine drug development. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3666-3669.
11. 1 receptor agonist, sumatriptan, for the treatment of migraine. Drug Dev. Res. 1992, 26, 235-240.
12. 1D receptor: discovery of compounds with potential anti-migraine properties. J. Med. Chem. 1995, 38, 3566-3580.
13. 1D receptors. J. Med. Chem, 1995, 38, 1799-1810.
14. 1 receptor. Proc. Br. Pharmacol. Soc. 1993, Abst C107 (Jan. 5-7, 1993, Cambridge).
15. (a) Erez, M.; Takemori, A. E.; Portoghese, P. S. Narcotic antagonist potency of bivalent ligands which contain β-naltrexamine. Evidence for bridging between proximal recognition sites. J. Med. Chem. 1982, 25, 847-849.
16. (b) Portoghese, P. S.; Ronsisvalle, G.; Larson, D. L.; Yim, C. B.; Sayre, L. M.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands as receptor probes. Life Sci. 1982, 31, 1283-1286.
17. (a) Shimohigashi, Y.; Costa, T.; Chen, H.-C.; Rodbard, D. Dimeric tetrapeptide enkephalins display extraordinary selectivity for the δ opiate receptor. Nature 1982, 297, 333-335.
18. (b) Costa, T.; Shimohigashi, Y.; Krumins, S. A.; Munson, P. J.; Rodbard, D. Dimeric pentapeptide enkephalin: a novel probe of delta opiate receptors. Life Sci. 1982, 31, 1625-1632.
19. (c) Shimohigashi, Y.; Costa, T.; Matsuura, S.; Chen, H.-C.; Rodbard, D. Dimeric enkephalins display enhanced affinity and selectivity for the delta opiate receptor. Mol. Pharmacol. 1982, 21, 558-563.
20. Lutz, R. A.; Cruciani, R. A.; Shimohigashi, Y.; Costa, T.; Kassis, S.; Munson, P. J.; Rodbard, D. Increased affinity and selectivity of enkephalin tripeptide (Tyr-D-Ala-Gly) dimers. Eur. J. Pharmacol. 1985, 41, 257-261.
21. (e) Costa, T.; Wüster, M.; Herz, A.; Shimohigashi, Y.; Chen, H.-C.; Rodbard, D. Receptor binding and biological activity of bivalent enkephalins. Biochem. Pharmacol. 1985, 34, 25-30.
22. (a) Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 10, 230-235.
23. (b) Portoghese, P. S. The role of concepts in structure-activity relationship studies of opioid ligands. J. Med. Chem. 1992, 35, 1927-1937.
24. Takemori, A. E.; Ho, B. Y.; Naeseth, J. S.; Portoghese, P. S. Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 1988, 246, 255-258.
25. 11-24 on steroidogenesis by synthesis of covalent dimeric conjugates. FEBS Lett. 1985, 183, 283-286.
26. (b) Kodama, H.; Shimohigashi, Y.; Sakaguchi, K.; Waki, M.; Takano, Y.; Yamada, A.; Hatae, Y.; Kamiga, H. Dimerization of neurokinin A and B COOH-terminal heptapeptide fragments enhanced the selectivity for tachykinin receptor subtypes. Eur. J. Pharmacol. 1988, 151, 317-320.
27. (c) Higuchi, Y.; Takano, Y.; Shimazaki, H.; Shimohigashi, Y.; Kodama, H.; Matsumoto, H.; Sakaguchi, K.; Nonako, S.; Sarto, R.; Waki, M.; Kamiya, H. Dimeric substance P analogue shows a highly potent activity of the in vivo salivary secretion in the rat. Eur. J. Pharmacol. 1989, 160, 413-416.
28. (d) Cheronis, J. C.; Whalley, E. T.; Nguyen, K. T.; Eubanks, S. R.; Allen, L. G.; Duggan, M. J.; Loy, S. D.; Bonham, K. A.; Blodgett, J. K. A new class of bradykinin antagonists: synthesis and in vitro activity of bis-succinimidoalkane peptide dimers. J. Med. Chem. 1992, 35, 1563-1572.
29. (e) Variek, R. J.; Stewart, J. M. Succinyl bisbradykinins: potent agonists with exceptional resistance to enzymatic degradation. In Peptides: Proceeding of the Eight American Peptide Symposium; Hruby, V. J., Rich, D. H., Eds.; Pierce Chemical Co.: Rockford, IL, 1983; pp 381-384.
30. 2 antagonist activity. J. Med. Chem. 1994, 37, 348-355.
31. (g) Carrithers, M. D.; Lerner, M. R. Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors. Chem. Biol. 1996, 3, 537-542.
32. Turnheim, K.; Kraupp, O. Pulmonary and systemic circulatory effects and β-adrenergic selectivity of hexaprenaline, salbutamol, oxyfedrine and isoproterenol. Eur. J. Pharmacol. 1971, 15, 231-239.
33. Fisher, L. E.; Rosenkranz, R. P.; Clark, R. D.; Muchowski, J. M.; McClelland, D. L.; Michel, A.; Caroon, J. M.; Galeazzi, E.; Eylen, R.; Whiting, R. L. N,N-6-bis-[2-(3,4-dihydroxybenzyl)-pyrrolidinyl]hexane, a potent, selective, orally active dopamine analog with hypotensive and diuretic activity. Bioorg. Med. Chem. Lett. 1995, 5, 2371-2376.
34. Le Boulluec, K.; Mattson, R. J.; Mable, C. D.; Mc Govern, R. T.; Nowak, H. P.; Gentile, A. J. Bivalent indoles exhibiting serotonergic binding affinity. Bioorg. Med. Chem. Lett. 1995, 5, 123-126.
35. 1D receptor agonists. Bioorg. Med. Chem. Lett. 1995, 5, 663-666.
36. 1D receptors. J. Med. Chem. 1995, 38, 3602-3607.
37. 1D receptors. Med. Chem. Res. 1995, 5, 680-689.
38. 1Dβ serotonin receptors. Med. Chem. Res. 1990, 5, 690-699.
39. Pauwels, P. J.; Van Compel, P.; Leysen, J. E. Activity of 5-HT receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa-cells. Biochem. Pharmacol. 1993, 45, 375-383.
40. 1D receptor agonists in the rabbit isolated saphenous vein. Br. J. Pharmacol. 1996, 119, 35-42.
41. 1Dβ receptor gene. Neurosci. Res. Commun. 1996, 18, 155-162.